TP53 and cancer: The use of potent and selective small molecule Mdm2 antagonists can disrupt the p53-Mdm2 interaction and activate the p53 pathway in cancer cells, resulting in cell cycle arrest, apoptosis, and inhibition of human tumor growth in nude mice (Vassilev et al., 2004).